The document discusses various treatments for rheumatoid arthritis including Disease-modifying antirheumatic drugs (DMARDs) such as Methotrexate, Leflunomide, Sulfasalazine, and Hydroxychloroquine, as well as biological DMARDs like Tumor necrosis factor (TNF) inhibitors. It notes the importance of early and aggressive treatment to prevent further joint damage and disability. Guidelines recommend starting with conventional synthetic DMARDs alone or in combination, and adding biological DMARDs if the disease is not adequately controlled.